Table 2. Treatment characteristics of the three age-based cohorts.
| AYA (15–39 y) | Middle age (40–64 y) | Older Adults (65+y) | Total | |
|---|---|---|---|---|
| Total number of patients | 220 | 991 | 278 | 1489 |
| Monotherapy | 76 (35%) | 298 (30%) | 98 (35%) | 479 (32%) |
| Combination therapy | 144 | 693 | 180 (65%) | 1017 (68%) |
| 2 drugs | 90 | 426 | 132 (47%) | 648 (44%) |
| 3 drugs | 54 | 262 | 46 (17%) | 362 (24%) |
| 4 drugs | 0 | 5 | 2 (<1%) | 7 (<1%) |
| Drug(s) given on protocol | ||||
| Non-FDA approved agent | 96 (44%) | 369 (37%) | 110 (40%) | 575 (69%) |
| Bevacizumab | 76 | 340 | 80 | 496 (33%) |
| TKI | 45 | 204 | 58 | 307 (21%) |
| Sorafenib | 20 | 87 | 21 | 128 (42%) |
| Cabozantinib | 7 | 51 | 15 | 73 (24%) |
Abbreviations: FDA Food and Drug Administration.